report details:
Published February 2005
176 pages
42 tables
Price: $3950.00
summary
The total U.S. market for reproductive technologies and products is estimated to be $6.5 billion in 2004. In 2009, revenues will likely reach $9.8 billion, rising at an average annual growth rate (AAGR) of 8.6%. The report contains:
A review of male and female reproductive health
An overview of standard pharmaceutical treatments, devices and technologies
An analysis of market size in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception and sexual dysfunction with forecasts to 2009
Market participants and current competitor market shares
An investigation of pipeline products and technologies.
table of contents:
INTRODUCTION
XV
STUDY GOALS AND OBJECTIVES
XV
REASONS FOR STUDY
XV
SCOPE OF STUDY
XV
METHODOLOGY AND INFORMATION SOURCES
XVI
ANALYST CREDENTIALS
XVI
RELATED BCC REPORTS
XVII
BCC ON-LINE SERVICES
XVII
DISCLAIMER
XVIII
SUMMARY
XIX
Summary Table:
TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
XX
Summary Figure:
TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
XX
INDUSTRY OVERVIEW
1
STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM
1
MALE
1
FEMALE
2
Female (Continued)
3
Female (Continued)
4
Female (Continued)
5
Neuroendocrine Regulation
6
Menarche
7
Menstruation Cycle
8
PHASES OF SEXUAL RESPONSES
9
Table 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
9
Male Sexual Response
9
Female Sexual Response
10
NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE SYSTEM
10
Estrogen
11
Progestogens
12
Testosterone
13
EFFECTS OF AGING
13
Effects of Aging (Continued)
14
ISSUES AND TRENDS OF REPRODUCTIVE HEALTH
15
CONTRACEPTIVE INSURANCE
15
LEGISLATIVE ACTIONS
16
Bioethics Commission
16
Bioethics Commission (Continued)
17
NEW USE FOR CONTRACEPTIVES
18
New Use for Contraceptives (Continued)
19
AGING AND INFERTILITY
20
DEATH BY CONTRACEPTIVE PATCH
20
SEXUAL DYSFUNCTION AND CANCER
21
INFERTILITY AND CANCER
22
Chemotherapy
22
Radiation
23
Prevention Strategies
24
Procreative Alternatives
24
Procreative Alternatives (Continued)
25
MARKETING TACTICS
26
MERCHANDIZING TARGETING WOMEN
26
COUNTERFEIT PRODUCTS
27
GENERIC PARTICIPATION
27
Table 2 PRESCRIPTION GENERIC DRUG APPROVALS BY COMPANY AND APPROVAL DATE 2003-2004
28
INTERNATIONAL ISSUES
28
SURPLUS EMBRYOS AND FETUSES
29
Surplus Embryos and Fetuses (Continued)
30
DESIGNER BABIES
31
Designer Babies (Continued)
32
STEM CELL AND OTHER CONTROVERSIAL ISSUES
33
Stem Cell and Other Controversial Issues (Continued)
34
Stem Cell and Other Controversial Issues (Continued)
35
CONTROVERSIAL DISPOSAL OF EMBRYOS
36
Controversial Disposal of Embryos (Continued)
37
DEMOGRAPHICS
38
Table 3 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
38
Figure 1 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
39
Table 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2003-2030 (THOUSANDS)
39
Figure 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030
40
Table 5 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND ESTIMATED 2005
41
Table 6 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980 TO 2000
42
Table 7 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
42
INFERTILITY MARKET
43
INTRODUCTION AND OVERVIEW OF INFERTILITY
43
DEFINITION OF INFERTILITY
43
ETIOLOGY OF INFERTILITY
43
INCIDENCE AND PREVALENCE OF INFERTILITY
43
EVALUATION OF FERTILITY
44
Male Factor
44
Male Factor (Continued)
45
Artificial Insemination
46
Artificial Insemination (Continued)
47
Artificial Insemination (Continued)
48
Vaginal and Cervical Factors
49
Immunological Factors
50
Uterine and Tubal Factors
51
Uterine and Tubal Factors (Continued)
52
Ovarian Factors
53
UNEXPLAINED INFERTILITY
54
MULTIPLE BIRTHS
55
METHODS OF TREATMENT
56
FERTILITY PHARMACEUTICALS
56
Introduction and Types
56
Introduction and Types (Continued)
57
Antagon
58
Bravelle
59
Cetrotide
59
Clomid
59
Clomid (continued)
60
Crinone
61
Factrel
61
Fertinex
61
Follistim
62
Gonal-F
62
Humegon
62
Lupron
63
Novarel
63
Ovidrel
63
Parlodel
63
Pregnyl
64
Profasi
64
Prometrium
64
Repronex
64
Serophene
65
Table 8 PRESCRIPTION FERTILITY DRUGS
65
Market Revenues and Forecast
66
Table 9 MARKET SIZE OF U.S. INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
66
Competitive Analysis
66
Table 10 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
67
Figure 3 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
67
Future Advancements in Infertility Products
68
Table 11 INFERTILITY DRUGS IN DEVELOPMENT
68
ARTIFICIAL REPRODUCTIVE TECHNOLOGIES
68
Types
69
IVF
69
Ovulation Induction
69
Oocyte Retrieval
70
Fertilization
70
Embryo Transfer
70
Results of IVF
71
GIFT
72
ZIFT
72
Wombs for Rent
73
Oocyte Donation
74
Frozen Embryos
75
U.S. Fertility Clinics
76
Table 12 2001 NATIONAL SUMMARY OF ARTIFICIAL REPRODUCTIVE THERAPIES
77
Table 13 2001 NATIONAL ARTIFICIAL REPRODUCTIVE THERAPIES CYCLE PROFILE
77
Table 14 2001 PREGNANCY SUCCESS RATES
78
Market Revenues and Forecast
79
Table 15 MARKET SIZE OF U.S. ARTIFICIAL REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
79
Future Trends in Artificial Reproductive Technology
79
Future Trends in Artificial ?Continued)
80
Future Trends in Artificial ?Continued)
81
FERTILITY DIAGNOSTICS
81
Types
82
Urine Studies
82
Pregnancy Testing
82
Ovulation Testing
83
Ovulation Testing (continued)
84
Sperm Testing
85
Hormone Studies
85
Blood Studies
85
Market Revenues and Forecast
86
Table 16 MARKET SIZE OF U.S. FERTILITY DIAGNOSTICS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
87
Competitive Analysis
87
Table 17 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
87
Figure 4 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
88
Future Advancements in Diagnostic Fertility Treatment
88
TOTAL INFERTILITY MARKET REVENUES AND FORECAST
89
Table 18 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
89
Figure 5 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
90
CONTRACEPTION MARKET
91
INTRODUCTION AND OVERVIEW OF CONTRACEPTION
91
INTRODUCTION AND?CONTINUED)
92
Table 19 CONTRACEPTIVE EFFECTIVENESS: THEORETICAL AND ACTUAL USE RATES
93
METHODS OF TREATMENT
93
PHARMACEUTICALS
93
Types
93
Oral Contraceptives
93
Oral Contraceptives (continued)
94
Oral Contraceptives (continued)
95
Oral Contraceptives (continued)
96
Table 20 MOST COMMONLY USED ORAL CONTRACEPTIVES, 2004
97
Alesse
97
Brevicon and Norinyl
98
Desogen
98
Estrostep
98
Levlen ED
98
Levora
99
Loestrin
99
LoOvral
99
Low-Ogestrel
99
Microgestin
100
Mircette
100
Necon
100
Nordette
100
Nor-QD
100
OrthoEvra
101
Ortho Micronor
101
Ortho TriCyclen
101
OrthoCept
101
Ovcon 35
102
Ovral
102
Seasonale
102
Tri-Levlen
103
Tri-Norinyl
103
Triphasil
103
Trivora
103
Yasmin 28
103
Zovia
104
Table 21 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
104
Table 21 (CONTINUED)
105
Table 22 PROGESTIN POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
105
Table 23 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
106
Other Drug Regimens for Contraception
106
Other Drug Regimens for?(continued)
107
Market Revenues and Forecast
108
Table 24 MARKET SIZE OF U.S. CONTRACEPTIVE PHARMACEUTICALS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
109
Competitive Analysis
109
Table 25 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ Millions)
110
Figure 6 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
110
DEVICES
111
Introduction and Types
111
Intrauterine Devices
111
NuvaRing
112
Market Revenues and Forecast
112
Table 26 MARKET SIZE OF U.S. CONTRACEPTIVE DEVICES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
113
Competitive Analysis
113
Table 27 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
113
Figure 7 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
114
FUTURE ADVANCEMENTS IN CONTRACEPTION
114
Table 28 CONTRACEPTIVE DRUGS IN DEVELOPMENT
114
Table 28 (CONTINUED)
115
YASMIN 20
115
C31G (SAVVY)
115
IMPLANON
115
LIBREL
116
THE 7-DAY TRANSLUCENT CONTRACEPTIVE PATCH
116
TESTOSTERONE UNDECANOATE
116
IMMUNO-CONTRACEPTIVE VACCINE
116
ORG 33628
117
TANAPROGET
117
USHERCELL
117
INVISIBLE CONDOM
117
TOTAL MARKET REVENUES AND FORECAST
118
Table 29 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
118
Figure 8 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
118
SEXUAL DYSFUNCTION MARKET
119
INTRODUCTION AND OVERVIEW
119
TYPES OF SEXUAL DYSFUNCTION
119
CAUSES OF SEXUAL DYSFUNCTION
120
DEMOGRAPHICS OF SEXUAL DYSFUNCTION
121
METHODS OF TREATMENT
121
PHARMACEUTICALS
121
Introduction and Types
121
Viagra
121
Cialis
122
Levitra
122
Uprima
122
Vasomax
123
Yohimbine
123
Caverject
123
MUSE
123
Market Revenues and Forecast
123
Table 30 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION PHARMACEUTICALS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
124
Competitive Analysis
124
Table 31 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
125
Figure 9 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
125
DEVICES
126
Introduction and Types
126
V.E.T. System and Assist
126
Erectaid Classic System
126
Imaging Agents
127
Market Revenues and Forecast
128
Table 32 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION DEVICES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
128
Competitive Analysis
128
Table 33 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
129
Figure 10 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
129
FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION
129
FUTURE ADVANCEMENTS IN?CONTINUED)
130
Table 34 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
131
Table 34 (CONTINUED)
132
ALPROX-TD
132
INTRINSA
133
ABT-724
133
ALISTA
133
TESTOSTERONE MDTS
134
APOMORPHINE
134
FEMPROX
134
LIBIGEL
135
PT-141
135
TA-1970
135
TESTOSTERONE VAGINAL RING
135
TOPIGLAN
136
TOSTRELLE
136
TOTAL MARKET REVENUES AND FORECAST
136
Table 35 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
137
Figure 11 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
137
PATENTS
138
PATENT ANALYSIS BY MANUFACTURER
138
Table 36 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
138
PATENTS BY APPLICATION
139
INFERTILITY TREATMENTS
139
CONTRACEPTION
139
SEXUAL DYSFUNCTION
139
LEADING MARKET MANUFACTURERS
139
Table 37 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT
140
TOTAL MARKET
141
TOTAL MARKET SIZE BY CATEGORY
141
Table 38 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
141
Figure 12 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
142
Table 39 TOTAL REVENUES, MARKET SHARE, AND NUMBER OF MANUFACTURERS OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2004 ($ MILLIONS)
143
Figure 13 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2004 (%)
143
Figure 14 U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY MARKET SEGMENT, 2004 (%)
144
INDUSTRY PARTICIPANTS BY CATEGORY
144
Table 40 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
144
Table 40 (CONTINUED)
145
TOTAL MARKET SIZE BY PRODUCT TYPE
145
Table 41 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
146
Figure 15 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
146
APPENDIX
147
SELECTED LIST OF US FERTILITY CLINICS
147
ALABAMA
147
ARIZONA
147
CALIFORNIA
148
COLORADO
149
CONNECTICUT
150
DISTRICT OF COLUMBIA
150
FLORIDA
150
GEORGIA
151
IDAHO
152
ILLINOIS
152
INDIANA
153
KANSAS
153
MAINE
153
MARYLAND
154
MASSACHUSETTS
154
MICHIGAN
154
MINNESOTA
155
MONTANA
155
NEVADA
155
NEW HAMPSHIRE
156
NEW JERSEY
156
NEW YORK
157
NORTH CAROLINA
157
OREGON
157
RHODE ISLAND
158
SOUTH CAROLINA
158
SOUTH DAKOTA
158
TEXAS
158
VIRGINIA
159
UTAH
159
WASHINGTON
159
COMPANY PROFILES
160
BAYER AG
160
BERLEX LABORATORIES, INC.
161
BRISTOL-MYERS SQUIBB CO.
161
CHURCH & DWIGHT COMPANY, INC.
162
ELI LILLY & CO.
162
ENDOCARE, INC.
163
GLAXOSMITHKLINE PLC
163
ICOS CORP.
164
NOVARTIS INTERNATIONAL AG
165
ORGANON INTERNATIONAL, INC.
165
ORTHO-MCNEIL PHARMACEUTICAL, INC.
166
PFIZER, INC.
166
PRINCETON BIOMEDITECH CORP.
167
SERONO S.A.
167
TAP PHARMACEUTICAL PRODUCTS, INC.
168
VIVUS, INC.
168
WATSON PHARMACEUTICALS, INC.
169
WYETH
169
LIST OF COMPANIES
170
Table 42 LIST OF COMPANIES
170
Table 42 (CONTINUED)
171
Table 42 (CONTINUED)
172
Table 42 (CONTINUED)
173
Table 42 (CONTINUED)
174
Table 42 (CONTINUED)
175
Table 42 (CONTINUED)
176
LIST OF TABLES
Summary Table:
TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
XX
Table 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
9
Table 2 PRESCRIPTION GENERIC DRUG APPROVALS BY COMPANY AND APPROVAL DATE 2003-2004
28
Table 3 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
38
Table 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2003-2030 (THOUSANDS)
39
Table 5 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND ESTIMATED 2005
41
Table 6 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980 TO 2000
42
Table 7 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
42
Table 8 PRESCRIPTION FERTILITY DRUGS
65
Table 9 MARKET SIZE OF U.S. INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
66
Table 10 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
67
Table 11 INFERTILITY DRUGS IN DEVELOPMENT
68
Table 12 2001 NATIONAL SUMMARY OF ARTIFICIAL REPRODUCTIVE THERAPIES
77
Table 13 2001 NATIONAL ARTIFICIAL REPRODUCTIVE THERAPIES CYCLE PROFILE
77
Table 14 2001 PREGNANCY SUCCESS RATES
78
Table 15 MARKET SIZE OF U.S. ARTIFICIAL REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
79
Table 16 MARKET SIZE OF U.S. FERTILITY DIAGNOSTICS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
87
Table 17 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
87
Table 18 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
89
Table 19 CONTRACEPTIVE EFFECTIVENESS: THEORETICAL AND ACTUAL USE RATES
93
Table 20 MOST COMMONLY USED ORAL CONTRACEPTIVES, 2004
97
Table 21 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
104
Table 22 PROGESTIN POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
105
Table 23 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
106
Table 24 MARKET SIZE OF U.S. CONTRACEPTIVE PHARMACEUTICALS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
109
Table 25 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ Millions)
110
Table 26 MARKET SIZE OF U.S. CONTRACEPTIVE DEVICES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
113
Table 27 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
113
Table 28 CONTRACEPTIVE DRUGS IN DEVELOPMENT
114
Table 29 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
118
Table 30 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION PHARMACEUTICALS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
124
Table 31 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
125
Table 32 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION DEVICES AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
128
Table 33 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
129
Table 34 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
131
Table 35 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
137
Table 36 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
138
Table 37 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT
140
Table 38 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
141
Table 39 TOTAL REVENUES, MARKET SHARE, AND NUMBER OF MANUFACTURERS OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2004 ($ MILLIONS)
143
Table 40 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
144
Table 41 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS'' SALES LEVELS, THROUGH 2009 ($ MILLIONS)
146
Table 42 LIST OF COMPANIES
170
LIST OF FIGURES
Summary Figure:
TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
XX
Figure 1 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
39
Figure 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030
40
Figure 3 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
67
Figure 4 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
88
Figure 5 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
90
Figure 6 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
110
Figure 7 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
114
Figure 8 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
118
Figure 9 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
125
Figure 10 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
129
Figure 11 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
137
Figure 12 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
142
Figure 13 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2004 (%)
143
Figure 14 U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY MARKET SEGMENT, 2004 (%)
144
Figure 15 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS'' SALES LEVELS, 2002-2009 ($ MILLIONS)
146